{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:44:19Z","timestamp":1775223859876,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\u201c139\u201d projects for training of high-level medical science talents; from Guangxi","award":["G202002007"],"award-info":[{"award-number":["G202002007"]}]},{"name":"the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province","award":["Z20201371"],"award-info":[{"award-number":["Z20201371"]}]},{"name":"the Youth Program of Scientifc Research Foundation of Guangxi Medical University Cancer Hospital","award":["2021-10"],"award-info":[{"award-number":["2021-10"]}]},{"name":"the Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi","award":["2022KY0079"],"award-info":[{"award-number":["2022KY0079"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02794-0","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:17:23Z","timestamp":1772187443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiation-induced hepatic toxicity from radiotherapy plus immune checkpoint inhibitors with targeted therapy in HCC patients: a propensity score-matched study"],"prefix":"10.1186","volume":"21","author":[{"given":"Rui-Jun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bang-De","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao-Mei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-Shen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Qiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Xiong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2794_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"key":"2794_CR2","doi-asserted-by":"crossref","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"2794_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"2794_CR4","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/cncr.21811","volume":"106","author":"MA Hawkins","year":"2006","unstructured":"Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer. 2006;106:1653\u201363.","journal-title":"Cancer"},{"key":"2794_CR5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s12072-021-10173-y","volume":"15","author":"LQ Li","year":"2021","unstructured":"Li LQ, Zhou Y, Huang Y, et al. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Int. 2021;15:630\u201341.","journal-title":"Hepatol Int"},{"key":"2794_CR6","first-page":"65","volume":"67","author":"FG Herrera","year":"2017","unstructured":"Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67:65\u201385.","journal-title":"CA Cancer J Clin"},{"key":"2794_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","volume":"16","author":"JX Li","year":"2022","unstructured":"Li JX, Su TS, Gong WF, et al. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. Hepatol Int. 2022;16:1179\u201387.","journal-title":"Hepatol Int"},{"key":"2794_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2018.06.002","volume":"52","author":"R Missiaen","year":"2018","unstructured":"Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol. 2018;52:107\u201316.","journal-title":"Semin Cancer Biol"},{"key":"2794_CR9","unstructured":"Ning C, Zhang X, Wang Y, et al. Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2023."},{"key":"2794_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A Nonrandomized, Open-label, phase II trial. Clin Cancer Res. 2021;27:1003\u201311.","journal-title":"Clin Cancer Res"},{"key":"2794_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22:977\u201390.","journal-title":"Lancet Oncol"},{"key":"2794_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13014-023-02309-1","volume":"18","author":"RJ Zhang","year":"2023","unstructured":"Zhang RJ, Zhou HM, Lu HY, et al. Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma. Radiat Oncol. 2023;18:129.","journal-title":"Radiat Oncol"},{"key":"2794_CR13","doi-asserted-by":"publisher","first-page":"680303","DOI":"10.3389\/fonc.2021.680303","volume":"11","author":"TS Su","year":"2021","unstructured":"Su TS, Li LQ, Liang SX, et al. A prospective study of liver regeneration after radiotherapy based on a new (Su\u2019S) target area delineation. Front Oncol. 2021;11:680303.","journal-title":"Front Oncol"},{"key":"2794_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.prro.2017.10.013","volume":"8","author":"TR Chapman","year":"2018","unstructured":"Chapman TR, Bowen SR, Schaub SK, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol. 2018;8:157\u201366.","journal-title":"Pract Radiat Oncol"},{"key":"2794_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.radonc.2018.02.031","volume":"129","author":"TS Su","year":"2018","unstructured":"Su TS, Luo R, Liang P, et al. A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma. Radiother Oncol. 2018;129:136\u201342.","journal-title":"Radiother Oncol"},{"key":"2794_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3904\/kjim.2016.412","volume":"33","author":"BG Jun","year":"2018","unstructured":"Jun BG, Kim YD, Cheon GJ, et al. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma. Korean J Intern Med. 2018;33:1093\u2013102.","journal-title":"Korean J Intern Med"},{"key":"2794_CR17","doi-asserted-by":"publisher","first-page":"e064688","DOI":"10.1136\/bmjopen-2022-064688","volume":"12","author":"K Wang","year":"2022","unstructured":"Wang K, Yu HM, Xiang YJ, et al. Efficacy and safety of radiotherapy combined with Atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ Open. 2022;12:e064688.","journal-title":"BMJ Open"},{"key":"2794_CR18","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","volume":"29","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zhou M, Tang J, et al. Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus. Clin Cancer Res. 2023;29:4088\u201397.","journal-title":"Clin Cancer Res"},{"key":"2794_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/JHC.S323302","volume":"8","author":"CM Liu","year":"2021","unstructured":"Liu CM, Huang BS, Yen YH, et al. Concurrent Sorafenib and radiotherapy versus radiotherapy alone for locally advanced hepatocellular carcinoma: A Propensity-Matched analysis. J Hepatocell Carcinoma. 2021;8:963\u201373.","journal-title":"J Hepatocell Carcinoma"},{"key":"2794_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ijrobp.2005.12.031","volume":"65","author":"SX Liang","year":"2006","unstructured":"Liang SX, Zhu XD, Xu ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65:426\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2794_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1478-3231.2012.02784.x","volume":"32","author":"HI Yoon","year":"2012","unstructured":"Yoon HI, Koom WS, Lee IJ, et al. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver Int. 2012;32:1165\u201371.","journal-title":"Liver Int"},{"key":"2794_CR22","doi-asserted-by":"publisher","first-page":"686621","DOI":"10.3389\/fonc.2021.686621","volume":"11","author":"L Zhong","year":"2021","unstructured":"Zhong L, Wu D, Peng W, et al. Safety of PD-1\/PD-L1 inhibitors combined with palliative radiotherapy and Anti-Angiogenic therapy in advanced hepatocellular carcinoma. Front Oncol. 2021;11:686621.","journal-title":"Front Oncol"},{"key":"2794_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.semradonc.2017.04.002","volume":"27","author":"P Munoz-Schuffenegger","year":"2017","unstructured":"Munoz-Schuffenegger P, Ng S, Dawson LA. Radiation-Induced liver toxicity. Semin Radiat Oncol. 2017;27:350\u20137.","journal-title":"Semin Radiat Oncol"},{"key":"2794_CR24","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","volume":"76","author":"CC Pan","year":"2010","unstructured":"Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76:S94\u2013100.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2794_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijrobp.2006.08.015","volume":"67","author":"TH Kim","year":"2007","unstructured":"Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:225\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2794_CR26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ijrobp.2009.09.009","volume":"78","author":"SH Son","year":"2010","unstructured":"Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78:1073\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2794_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.01.221","volume":"97","author":"M Velec","year":"2017","unstructured":"Velec M, Haddad CR, Craig T, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97:939\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02794-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:45:21Z","timestamp":1775220321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02794-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2794"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02794-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"18 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were carried out in accordance with the Declaration of Helsinki. This retrospective study was approved by the Institutional Review Board of Guangxi Medical University Cancer Hospital, which waived the requirement for written informed consent (number LW2023186). Patient consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}